Literature DB >> 17967304

Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.

Asif Harsolia1, Carlos Vargas, Di Yan, Donald Brabbins, David Lockman, Jian Liang, Gary Gustafson, Frank Vicini, Alvaro Martinez, Larry L Kestin.   

Abstract

PURPOSE: To identify factors predictive for chronic urinary toxicity secondary to high-dose adaptive three-dimensional conformal radiation. METHODS AND MATERIALS: From 1999 to 2002, 331 consecutive patients with clinical Stage II-III prostate cancer were prospectively treated (median dose, 75.6 Gy). The bladder was contoured, and the bladder wall was defined as the outer 3 mm of the bladder solid volume. Toxicity was quantified according to the National Cancer Institute Common Toxicity Criteria 2.0. Median follow-up was 1.6 years.
RESULTS: The 3-year rates of Grade > or =2 and Grade 3 chronic urinary toxicity were 17.0% and 3.6%, respectively. Prostate volume, confidence-limited patient-specific planning target volume, bladder wall volume, and acute urinary toxicity were all found to be accurate predictors for chronic urinary toxicity. The volume of bladder wall receiving > or =30 Gy (V30) and > or =82 Gy (V82), along with prostate volume, were all clinically useful predictors of Grade > or =2 and Grade 3 chronic urinary toxicity and chronic urinary retention. Both Grade > or =2 (p = 0.001) and Grade 3 (p = 0.03) acute urinary toxicity were predictive for the development of Grade > or =2 (p = 0.001, p = 0.03) and Grade 3 (p = 0.05, p < 0.001) chronic urinary toxicity. On Cox multivariate analysis the development of acute toxicity was independently predictive for the development of both Grade > or =2 and Grade 3 chronic urinary toxicity.
CONCLUSIONS: Acute urinary toxicity and bladder wall dose-volume endpoints are strong predictors for the development of subsequent chronic urinary toxicity. Our recommendation is to attempt to limit the bladder wall V30 to <30 cm(3) and the V82 to <7 cm(3) when possible. If bladder wall information is not available, bladder solid V30 and V82 may be used.

Entities:  

Mesh:

Year:  2007        PMID: 17967304     DOI: 10.1016/j.ijrobp.2007.04.076

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  24 in total

1.  Dose-volume Histogram-based Predictors for Hematuria and Rectal Hemorrhage in Patients Receiving Radiotherapy After Radical Prostatectomy.

Authors:  Katsuyuki Shirai; Masato Suzuki; Keiko Akahane; Yuta Takahashi; Masahiro Kawahara; Erika Yamada; Masaru Wakatsuki; Kazunari Ogawa; Satrou Takahashi; Kyosuke Minato; Kohei Hamamoto; Kimitoshi Saito; Masashi Oshima; Tsuzumi Konishi; Yuhki Nakamura; Satoshi Washino; Tomoaki Miyagawa
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer.

Authors:  Pirus Ghadjar; Michael J Zelefsky; Daniel E Spratt; Per Munck af Rosenschöld; Jung Hun Oh; Margie Hunt; Marisa Kollmeier; Laura Happersett; Ellen Yorke; Joseph O Deasy; Andrew Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

Review 3.  Adaptive radiation therapy for prostate cancer.

Authors:  Michel Ghilezan; Di Yan; Alvaro Martinez
Journal:  Semin Radiat Oncol       Date:  2010-04       Impact factor: 5.934

4.  Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.

Authors:  A Zapatero; M Roch; D Büchser; P Castro; L Fernández-Banda; G Pozo; O Liñán; C Martin de Vidales; A Cruz-Conde; F García-Vicente
Journal:  Clin Transl Oncol       Date:  2017-04-03       Impact factor: 3.405

5.  Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer.

Authors:  Nadine Housri; Holly Ning; John Ondos; Peter Choyke; Kevin Camphausen; Deborah Citrin; Barbara Arora; Uma Shankavaram; Aradhana Kaushal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-06       Impact factor: 7.038

6.  Delineating the inner bladder surface using uniform contractions from the outer surface under variable bladder filling conditions.

Authors:  Tara Rosewall; Andrew Bayley; Charles Catton; Peter Chung; Geoffrey Currie; Robert Heaton; Janelle Wheat; Michael Milosevic
Journal:  Br J Radiol       Date:  2015-07-24       Impact factor: 3.039

7.  A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints.

Authors:  Awad A Ahmed; Brian Egleston; Pino Alcantara; Linna Li; Alan Pollack; Eric M Horwitz; Mark K Buyyounouski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-09       Impact factor: 7.038

8.  Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer.

Authors:  Ane L Appelt; Søren M Bentzen; Anders Jakobsen; Ivan R Vogelius
Journal:  Acta Oncol       Date:  2014-06-30       Impact factor: 4.089

9.  Perception of body odor-an overlooked consequence of long-term gastrointestinal and urinary symptoms after radiation therapy for prostate cancer.

Authors:  D Alsadius; C Olsson; N Pettersson; S L Tucker; U Wilderäng; G Steineck
Journal:  J Cancer Surviv       Date:  2013-08-23       Impact factor: 4.442

10.  Impact of bladder volume on acute genitourinary toxicity in intensity modulated radiotherapy for localized and locally advanced prostate cancer.

Authors:  Arne Grün; Michael Kawgan-Kagan; David Kaul; Harun Badakhshi; Carmen Stromberger; Volker Budach; Dirk Böhmer
Journal:  Strahlenther Onkol       Date:  2018-11-15       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.